Filtered By:
Drug: Vytorin

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Conclusions This trial is evaluating LDL-C lowering beyond previously targeted LDL-C levels. The results depend on achieving the desired separation of LDL-C with ezetimibe and on the assumption that ezetimibe’s lowering of LDL-C will have similar event reduction efficacy as the LDL-C lowering from a statin. The results could affect future therapies and guidelines.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
CONCLUSION: The results of this real-world retrospective analysis of 14 patients with hyperlipidemia demonstrated reductions in TG, LDL-C, TC, and non-HDL-C levels, with mixed results in HDL-C levels, after switching from OM3EE to IPE. PMID: 24977343 [PubMed - indexed for MEDLINE]
Source: Postgraduate Medicine - November 28, 2014 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Rapid analysis of hypolipidemic drugs in a live zebrafish assay
In this study, taking advantage of the transparency of larval zebrafish, we developed a zebrafish hyperlipidemia model for drug screening and efficacy assessment. Zebrafish at 5 d.p.f (days post fertilization) were fed with 0.1% egg yolk for 48h (hours), followed by drug treatment for 24h or 48h. Tested drugs were administered into the zebrafish by direct soaking. Drug effect was evaluated based on quantitative analysis of Oil Red O (ORO) in zebrafish vena caudalis. Results All 5 human hypolipidemic drugs (simvastatin, lovastatin, ezetimibe, bezafibrate, hyodesoxycholic acid) showed significant hypolipidemic effects (p &a...
Source: Journal of Pharmacological and Toxicological Methods - December 13, 2014 Category: Drugs & Pharmacology Source Type: research

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders. Trial registration number ClinicalTrials.gov identifier: NCT00092677.
Source: Heart - January 14, 2015 Category: Cardiology Authors: Cramariuc, D., Rogge, B. P., Lonnebakken, M. T., Boman, K., Bahlmann, E., Gohlke-Barwolf, C., Chambers, J. B., Pedersen, T. R., Gerdts, E. Tags: Open access, Drugs: cardiovascular system, Echocardiography, Hypertension, Interventional cardiology, Aortic valve disease, Clinical diagnostic tests, Epidemiology Valvular heart disease Source Type: research

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era
Conclusions In lipid-lowering therapy post-MI, ezetimibe and statin combination therapy improved MACCE with or without revascularization compared with statin monotherapy. These findings suggest that post-MI secondary prevention should be more intensive.
Source: IJC Heart and Vasculature - August 2, 2015 Category: Cardiology Source Type: research

IMPROVE-IT: Diabetics Benefit With Ezetimibe, but Is It Enough?IMPROVE-IT: Diabetics Benefit With Ezetimibe, but Is It Enough?
Diabetics saw reductions in MI and stroke with ezetimibe in a new analysis of IMPROVE-IT. But one expert said it's still not enough to convince him to use it; more refined risk assessment is needed. Medscape Medical News
Source: Medscape Medical News Headlines - August 31, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT.
CONCLUSIONS: Significantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory dual LDL-C and hs-CRP targets than patients treated with simvastatin alone. Reaching both LDL-C and hs-CRP targets was associated with improved outcomes after multivariable adjustment. Clinical Trial Registration-URL: http://www.clinicaltrials.gov; Unique identifier: NCT00202878. PMID: 26330412 [PubMed - as supplied by publisher]
Source: Circulation - September 1, 2015 Category: Cardiology Authors: Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E Tags: Circulation Source Type: research

Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome
Commentary on: Cannon CP, Blazing MA, Giugliano RP, et al., IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–97. Context Use of statin therapy to treat dyslipidemia in patients with established coronary artery disease is the standard of care worldwide. Given the negative results of a number of trials that tested the use of adjuvant lipid-lowering therapies against a statin background, there has been great scepticism about whether or not non-statin drugs provide incremental benefit.1–3 Ezetimibe inhibits the absorption of both dietary and bili...
Source: Evidence-Based Medicine - September 24, 2015 Category: Internal Medicine Authors: Toth, P. P. Tags: Health policy, Epidemiologic studies, Genetics, Immunology (including allergy), Vaccination / immunisation, Stroke, Diet, Ischaemic heart disease, Health economics, Health service research, Lipid disorders Therapeutics/Prevention Source Type: research

Do statins interfere with the flu vaccine?
Statins are powerful, unusual, and, like El Niño and Tom Cruise, not well understood. Statins have a huge upside. They improve survival after heart attacks and lower the risk of recurrent strokes. They are also the only cholesterol-lowering medications that have been clearly shown to reduce heart attacks and deaths in high-risk patients without heart disease. In addition to reducing cholesterol, statins also lower levels of inflammation in the body. Reducing inflammation probably helps statins to prevent heart attack and stroke. However, evidence is emerging that these statin effects may also have a downside, hindering th...
Source: New Harvard Health Information - November 30, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Drugs and Supplements Health Heart Health Vaccines flu vaccine statins Source Type: news

FDA Advisors: Reject Secondary-Prevention Ezetimibe IndicationFDA Advisors: Reject Secondary-Prevention Ezetimibe Indication
UPDATED // Noting that the secondary-prevention IMPROVE-IT trial's results weren't "clinically substantial," the panel also voiced concerns with hemorrhagic stroke risk and missing study data. Heartwire from Medscape
Source: Medscape Cardiology Headlines - December 15, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Efficacy of ezetimibe: A real effect?
We do not agree with the methods and the conclusions of the systematic review of Savarese et al. [1]. Their meta-analysis of seven randomized controlled trials tests the safety and the efficacy of ezetimibe (E), added to a statin, in comparison indifferently versus placebo or active treatment and shows a favorable effect of E on risks of major non-fatal endpoints (myocardial infarction RR: 0.865, 95% CI: 0.801–0.934; stroke RR: 0.840, 95% CI: 0.744–0.949), with a neutral effect on mortality outcomes (all-cause death RR: 1.003, 95% CI: 0.954–1.055; CV death RR: 0.958, 95% CI: 0.879–1.044) and new cancer risk (RR: 1....
Source: International Journal of Cardiology - February 24, 2016 Category: Cardiology Authors: Alberto Donzelli, Alessandro Battaggia Tags: Correspondence Source Type: research

Abstract 112: Adherence and Persistence with Statins in Patients with ASCVD Session Title: Abstract Poster Session I and Reception
Conclusions: While patients remained on their first statin (or ezetimibe) therapy for a substantial period of time, a large proportion of patients eventually discontinue therapy. Overall, adherence was high, indicating that ASCVD patients are compliant with their LLT. Interventions and new treatments to improve lipid lowering therapy seem necessary in patients with ASCVD.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: Burke, J. P., Paoli, C. J., McPheeters, J., Gandra, S. R., Simpson, R. J. Tags: Session Title: Abstract Poster Session I and Reception Source Type: research

New drug 'effective' for those with intolerable statin side effects
Conclusion The main results of this study relate to the lipid-lowering effects of two alternative non-statin medications. However, it highlights the muscle-related adverse effects that can occur with statins. The study is carefully designed and has many strengths, including: a washout period between drugs to remove any residual effects double-blind design throughout so people didn't know what they were taking sufficient duration for each phase of the study (10 and 24 weeks) to allow effects to develop a good sample size – the researchers calculated beforehand how many people would need to be recruited to ena...
Source: NHS News Feed - April 4, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

Farewell to the fasting cholesterol test?
At a recent meeting I offered a visitor lunch which she declined with obvious regret. She was hungry, and it was noon. But she was headed to her annual physical, and eating beforehand would mean returning another morning for a fasting cholesterol level. Most of us can relate to her annoyance, but thankfully this may soon be a thing of the past. Doctors have traditionally ordered cholesterol tests to be drawn after an overnight fast. But this requirement causes a significant burden on both sides of the health care equation. Most people hate to fast. Skipping meals is particularly difficult for active people, people with dia...
Source: New Harvard Health Information - June 16, 2016 Category: Consumer Health News Authors: Naomi D. L. Fisher, MD Tags: Health Heart Health Prevention Screening Tests and procedures Source Type: news